Sustained release formulations are becoming more popular now days for the delivery of non-steroidal anti-inflammatory drugs (NSAIDs) because of their ability to maintain therapeutic effective drug concentration for prolonged duration with low dosing frequency and side effects associated with NSAIDs. The present study was attempted to develop Sustained release tablets of a model NSAID drug, Etodolac. Etodolac Sustained release tablets were prepared by Gellan Gum (A, mg), Sodium CMC (B, mg), Xyloglucan (C, ml), Xanthan Gum (D, ml), MCC (E, ml), Talc (F, rpm), Orange flavour (G, rpm), Aspartame (H, rpm), Magnesium stearate (I, rpm). The granules were evaluated for flow properties by evaluating bulk density, tapped density, Carr’s index, Hausner’s ratio and angle of repose. The tablets were evaluated for drug polymer compatibility study by FTIR, diameter, weight variation test, hardness, friability, disintegration test, SEM, Swelling Index, In vitro drug release, release kinetics, stability studies and Plackett-Burman Experimental Design was also applied to find the optimized formulation. The FTIR study revealed that no such interactions being taking place in between drug and polymers. The flow property of granules of all tablet batches was found to be good. All the tablet formulations had good tablet physiochemical properties. The swelling of the tablets was also found optimum. From the results of in-vitro study, it was concluded that Etodolac Sustained release tablet provided most sustained release of Etodolac over extended period of time with aid of greater stability.